196 related articles for article (PubMed ID: 37414154)
1. Insulin-degrading enzyme: Roles and pathways in ameliorating cognitive impairment associated with Alzheimer's disease and diabetes.
Tian Y; Jing G; Zhang M
Ageing Res Rev; 2023 Sep; 90():101999. PubMed ID: 37414154
[TBL] [Abstract][Full Text] [Related]
2. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Qiu WQ; Folstein MF
Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206
[TBL] [Abstract][Full Text] [Related]
3. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
Tang WJ
Trends Endocrinol Metab; 2016 Jan; 27(1):24-34. PubMed ID: 26651592
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism Rs2421943 of the Insulin-Degrading Enzyme Gene and the Risk of Late-Onset Alzheimer's Disease.
Šerý O; Zeman T; Hálová A; Janout V; Janoutová J; Lochman J; Balcar VJ
Curr Alzheimer Res; 2022; 19(3):236-245. PubMed ID: 35236268
[TBL] [Abstract][Full Text] [Related]
5. New Insights on the Regulation of the Insulin-Degrading Enzyme: Role of microRNAs and RBPs.
Martín-Martín Y; Pérez-García A; Torrecilla-Parra M; Fernández-de Frutos M; Pardo-Marqués V; Casarejos MJ; Busto R; Ramírez CM
Cells; 2022 Aug; 11(16):. PubMed ID: 36010613
[TBL] [Abstract][Full Text] [Related]
6. The extracellular matrix enriched with membrane metalloendopeptidase and insulin-degrading enzyme suppresses the deposition of amyloid-beta peptide in Alzheimer's disease cell models.
Zhang S; Xiao T; Yu Y; Qiao Y; Xu Z; Geng J; Liang Y; Mei Y; Dong Q; Wang B; Wei J; Suo G
J Tissue Eng Regen Med; 2019 Oct; 13(10):1759-1769. PubMed ID: 31151136
[TBL] [Abstract][Full Text] [Related]
7. Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1.
Schilling MA
J Alzheimers Dis; 2016; 51(4):961-77. PubMed ID: 26967215
[TBL] [Abstract][Full Text] [Related]
8. Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer's disease and brain aging.
Corraliza-Gomez M; Bermejo T; Lilue J; Rodriguez-Iglesias N; Valero J; Cozar-Castellano I; Arranz E; Sanchez D; Ganfornina MD
J Neuroinflammation; 2023 Oct; 20(1):233. PubMed ID: 37817156
[TBL] [Abstract][Full Text] [Related]
9. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
Pivovarova O; Höhn A; Grune T; Pfeiffer AF; Rudovich N
Ann Med; 2016 Dec; 48(8):614-624. PubMed ID: 27320287
[TBL] [Abstract][Full Text] [Related]
10. The Insulin-Degrading Enzyme from Structure to Allosteric Modulation: New Perspectives for Drug Design.
Tundo GR; Grasso G; Persico M; Tkachuk O; Bellia F; Bocedi A; Marini S; Parravano M; Graziani G; Fattorusso C; Sbardella D
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892174
[TBL] [Abstract][Full Text] [Related]
11. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Li H; Wu J; Zhu L; Sha L; Yang S; Wei J; Ji L; Tang X; Mao K; Cao L; Wei N; Xie W; Yang Z
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29222348
[TBL] [Abstract][Full Text] [Related]
12. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
[TBL] [Abstract][Full Text] [Related]
13. Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease?
Liu Z; Zhu H; Fang GG; Walsh K; Mwamburi M; Wolozin B; Abdul-Hay SO; Ikezu T; Leissring MA; Qiu WQ
J Alzheimers Dis; 2012; 29(2):329-40. PubMed ID: 22232014
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review.
Azam MS; Wahiduzzaman M; Reyad-Ul-Ferdous M; Islam MN; Roy M
Pharm Res; 2022 Apr; 39(4):611-629. PubMed ID: 35378698
[TBL] [Abstract][Full Text] [Related]
15. Links between Alzheimer's disease and diabetes.
Sun MK; Alkon DL
Drugs Today (Barc); 2006 Jul; 42(7):481-9. PubMed ID: 16894402
[TBL] [Abstract][Full Text] [Related]
16. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology.
Zhao Z; Ho L; Wang J; Qin W; Festa ED; Mobbs C; Hof P; Rocher A; Masur S; Haroutunian V; Pasinetti GM
FASEB J; 2005 Dec; 19(14):2081-2. PubMed ID: 16186174
[TBL] [Abstract][Full Text] [Related]
17. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P
J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774
[TBL] [Abstract][Full Text] [Related]
18. Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models.
Stargardt A; Gillis J; Kamphuis W; Wiemhoefer A; Kooijman L; Raspe M; Benckhuijsen W; Drijfhout JW; Hol EM; Reits E
Aging Cell; 2013 Jun; 12(3):499-507. PubMed ID: 23534431
[TBL] [Abstract][Full Text] [Related]
19. Examining the effects of ovarian hormone loss and diet-induced obesity on Alzheimer's disease markers of amyloid-β production and degradation.
Hayward GC; Baranowski BJ; Marko DM; MacPherson REK
J Neurophysiol; 2021 Apr; 125(4):1068-1078. PubMed ID: 33534663
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Aβ by insulin degrading enzyme (IDE) in Alzheimer's disease.
Del Campo M; Stargardt A; Veerhuis R; Reits E; Teunissen CE
Neurosci Lett; 2015 Mar; 589():47-51. PubMed ID: 25597881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
